These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date 2006-001707-11 Prospective, randomized, pharmacological intervention study; evaluating the effect of the angiotensin II-receptor (AT1) blocker candesartan versus placebo in prevention of trastuzumab-associated cardi... bad-data
Ongoing 2006-003466-34 Phase III randomised clinical trial for stage III ovarian carcinoma randomising between secondary debulking surgery with or without hyperthermic intraperitoneal chemotherapy (OVHIPEC-I) not-yet-due
Ongoing 2006-004130-32 A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer (CRITICS-study: ChemoRadioth... not-yet-due
Ongoing 2006-005197-51 Accelerated growth of synchronous colorectal liver metastases: effects of neo-adjuvant therapy not-yet-due
Ongoing 2006-006491-38 Sunitinib prior to nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ not-yet-due
Completed, but no date 2007-000412-82 PHARMACOGENOMIC AND PHARMACOKINETIC SAFETY AND COST-SAVING ANALYSIS IN PATIENTS TREATED WITH FLUOROPYRIMIDINES bad-data
Exempt 2007-003894-18 Open-label, randomised, multi-center study investigating Cetuximab, in combination with concurrent chemo- / radiotherapy in locally advanced non-small cell lung carcinoma not-yet-due
Ongoing 2007-007030-20 RANDOMIZED PHASE II/III STUDY OF SECOND-LINE ENDOCRINE TREATMENT FOLLOWED BY CAPECITABINE VERSUS CAPECITABINE FOLLOWED BY ENDOCRINE TREATMENT IN PATIENTS WITH METASTATIC ER POSITIVE BREAST CANCER not-yet-due
Ongoing 2008-000644-13 A randomized, prospective trial of 2-6 weeks pre-operative hormonal treatment for hormone receptor positive breast cancer: Anastrozole +/- Fulvestrant or Tamoxifen Exposure - response in molecular pro... not-yet-due
Ongoing 2008-000987-18 Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study not-yet-due
Ongoing 2009-015238-31 RANDOMIZED PHASE II/III STUDY OF INDIVIDUALIZED NEOADJUVANT CHEMOTHERAPY IN ‘TRIPLE-NEGATIVE’ BREAST TUMORS not-yet-due
Ongoing 2009-018246-38 Phase II trial evaluating combined image guided radiotherapy with Panitumumab (Vectibix®) in patients with muscle invasive transitional cell carcinoma of the bladder not-yet-due
Ongoing 2010-019106-16 Phase II and Pharmacological Study with Wee-1 Inhibitor AZD1775 Combined with Carboplatin in Patients with p53 Mutated Epithelial Ovarian Cancer not-yet-due
Completed, but no date Terminated 2010-021885-31 Randomized Phase II Study Using a Non-myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Tumor Infiltrating Lymphocytes and Interleukin-2 in Metastatic Melanoma’ bad-data
Ongoing 2010-022699-30 Phase II Study of Docetaxel, Oxaliplatin, Capecitabine with Bevacizumab and Trastuzumab in case of human epidermal growth factor receptor 2 (HER2)-positivity in Patients with Locally Advanced or Metas... not-yet-due
Ongoing 2010-022703-22 Local immunotherapy by the synergism of monobenzone and imiquimod cream (MI) for cutanous metastases in stage III-IV melanoma patients. not-yet-due
Exempt 2011-002941-36 Multicenter phase 1/2a study using T-cell receptor gene therapy in metastatic melanoma not-yet-due
Ongoing 2011-004200-38 Phase II study exploring safety and efficacy of the combination of ipilimumab with radiofrequency ablation (RFA) in patients with unresectable uveal melanoma liver metastasis (SECIRA-UM) not-yet-due
Ongoing 2012-000437-39 A randomized study with Cisplatinum or Cetuximab and standard or adaptive high dose radiotherapy for advanced head and neck cancer. not-yet-due
Ongoing 2012-000838-19 High-dose alkylating chemotherapy in oligo-metastatic breast cancer harboring homologous recombination deficiency not-yet-due
Ongoing 2012-002392-33 Phase I Hybrid study: combined stereotactic radiotherapy and conventional fractionation in stage II and III non small cell lung cancer with peripheral tumors smaller than 5 cm not-yet-due
Completed, but no date Terminated 2012-005096-13 Clinical and pharmacological feasibility study with 2B3-101 in patients with breast cancer bad-data
Ongoing 2012-005653-22 TachoSil patch application as replacement of closed suction wound drainage by parotid gland surgery; a prospective study. not-yet-due
Exempt 2013-000138-37 Treatment of PERItoneal dissemination in Stomach Cancer patients with cytOreductive surgery and hyperthermic intraPEritoneal chemotherapy not-yet-due
Completed, but no date 2013-001567-24 Use of individual PK-guided pazopanib dosing: A feasibility study in patients with advanced solid tumors bad-data
Ongoing 2013-002616-28 Cytoreductive treatment of dabrafenib combined with trametinib to allow complete surgical resection in patients with BRAF mutated, prior unresectable stage III or IV melanoma not-yet-due
Exempt 2013-003299-10 Phase I/II study with the combination of dacomitinib and PD-0325901 in 2018-08-07 not-yet-due
Exempt 2013-003947-51 Phase I/prospective randomized phase II trial Of the Safety and Efficacy of tamoxifen in combination with the Isoform selective Pi3K inhibitor GDC-0032 compared with tamoxifen alONe in hormone recepto... not-yet-due
Ongoing 2013-005406-54 Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukin-2 to standard ipilimumab tr... not-yet-due
Exempt 2013-005590-41 A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA-1 or -2 mutated Her2 negative advanced breast cancer a... not-yet-due
Ongoing 2013-005621-24 PeRsOnalized treatment fOr patients with pleural eFfusions due to malignant pleural mesothelioma or lung cancer in second or third line. An open label phase II study (Acronym: the PROOF study) not-yet-due
Ongoing 2014-000476-26 Dynamics of Androgen Receptor genomics and transcriptomics after neoadjuvant androgen ablation (DARANA) not-yet-due
Exempt 2014-001855-22 Phase I/II study with the combination of afatinib and selumetinib in advanced KRAS mutant positive and PIK3CA wildtype non-small cell lung cancer and colorectal cancer not-yet-due
Exempt 2014-002209-39 Phase I/II study with lapatinib plus trametinib in patients with metastatic not-yet-due
Ongoing 2014-002616-16 Pilot for high-resolution SPECT imaging of breast cancer lumpectomy specimens for 3D identification and quantification of resection margins not-yet-due
Ongoing 2014-002800-25 Zirconium-89 Trastuzumab tracer uptake in metastatic breast cancer: A pilot study. not-yet-due
Not reported 2014-003811-13 Selecting cancer patients for treatment using Tumor Organoids, the SENSOR study 2019-03-19 due-trials
Ongoing 2014-003935-20 A single arm phase II study of Nivolumab in patients with progressive malignant pleural mesothelioma: interim biopsy analysis to determine efficacy. Acronym: NivoMes Study not-yet-due
Ongoing 2014-004735-39 Phase II Study of cisplatin and everolimus in patients with metastatic or unresectable neuroendocrine carcinomas (NEC) of extrapulmonary origin not-yet-due
Completed, but no date 2014-005064-15 Safety, feasibility and cost-effectiveness of genotype-directed individualized dosing of fluoropyrimidines bad-data
Ongoing 2014-005118-49 Randomized Phase II, 2-arm study of Pembrolizumab after high dose radiation (SBRT) versus Pembrolizumab alone in patients with advanced non-small cell lung cancer. Acronym: PEMBRO-RT study not-yet-due
Ongoing 2015-001969-49 Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple-negative breast cancer (TNBC) patients: TONIC-trial not-yet-due
Ongoing 2015-002026-39 The Effect of Prehydration on the Pharmacokinetics of Low-dose Cisplatin not-yet-due
Ongoing 2015-003120-31 Phase 2 Study Comparing Pembrolizumab with Intermittent/Short-term Dual MAPK Pathway Inhibition Plus Pembrolizumab in patients harboring the BRAFV600 mutation (IMPemBra) not-yet-due
Listed as ongoing, but also has a completion date 2015-004134-95 Phase II clinical study of concurrent PAzopanib for non-metastatic SArcoma patients to be treated with RadioTherapy, localized in the extremities, trunk and chest wall or the head and neck region 2019-04-03 bad-data
Ongoing 2015-004398-33 The Drug Rediscovery Protocol (DRUP trial) A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti... not-yet-due
Ongoing 2015-004627-31 A multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery vs. neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery vs. neo-adjuvant chemoradiot... not-yet-due
Exempt 2015-005339-42 Safety, immunogenicity and clinical response of sig-HELP-E6SH/E7SH-kdel, injected in the epidermis by DNA tattoo, in HPV16-positive vulvar intraepithelial neoplasia: a phase I/II study not-yet-due
Ongoing 2015-005695-15 Treatment of PERitoneal dissemination in Stomach Cancer patients with cytOreductive surgery and hyperthermic intraPEritoneal chemotherapy: the PERISCOPE II study not-yet-due
Ongoing 2015-005840-33 HDAC inhibitor vorinostat in resistant BRAF V600 mutated advanced melanoma not-yet-due
Ongoing 2016-001599-31 Ipilimumab and Nivolumab in the Treatment of malignant Pleural Mesothelioma: a Phase II study not-yet-due
Ongoing 2016-001852-23 A feasibility study of niraparib for advanced, BRCA1-like, HER2-negative breast cancer patients not-yet-due
Ongoing 2016-001984-35 Multicenter Phase 2 Study to Identify of the Optimal neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo) not-yet-due
Exempt 2016-002349-50 Phase I/II study with galunisertib (LY2157299) combined with capecitabine in patients with advanced chemotherapy resistant colorectal cancer and an 2019-08-05 not-yet-due
Completed, report not yet due 2016-002364-13 MoTriColor: A phase II study of vinorelbine in advanced BRAF-like colon cancer 2020-03-17 not-yet-due
Ongoing 2016-002493-13 Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy not-yet-due
Ongoing 2016-002940-17 Nivolumab, Ipilimumab and COX2-inhibition in early stage colon cancer: an unbiased approach for signals of sensitivity not-yet-due
Ongoing 2016-003790-18 Feasibility trial on combination of platinum doublets and hypofractionated radiotherapy for locally-advanced stage and / or inoperable non-small cell lung carcinoma not-yet-due
Ongoing 2016-004700-56 Exploratory study of neo-adjuvant treatment with carboplatin, paclitaxel and pembrolizumab in primary stage IV serous ovarian cancer not-yet-due
Ongoing 2016-004963-38 A randomized, open label, Phase IIB trial of Optimal Sequencing of Treatment Options for Poor Risk Metastasized Castration Resistant Prostate Cancer Previously Treated with Docetaxel (OSTRICh trial) not-yet-due
Not reported 2016-005252-21 Increasing pazopanib exposure by splitting intake moments 2019-03-12 due-trials
Ongoing 2017-001428-23 AssessinG Efficacy of carboplatin and ATezOlizumab in metastatic Lobular breast cancer: GELATO-trial not-yet-due
Ongoing 2017-003102-40 Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility not-yet-due
Ongoing 2017-003854-17 Neoadjuvant capecitabine, oxaliplatin, docetaxel and atezolizumab in non-metastatic, resectable gastric and GE-junction cancer. not-yet-due
Ongoing 2018-000603-17 PERICLES (PEnile cancer Radio- and Immunotherapy CLinical Exploration Study) – a Phase 2 study of atezolizumab with or without radiotherapy in penile cancer not-yet-due
Ongoing 2018-001521-97 Phase II single arm study of afatinib in combination with cetuximab in EGFR exon 20 insertion positive non-small-cell lung cancer not-yet-due
Ongoing 2018-002463-25 Neoadjuvant treatment in rectal cancer with radiotherapy followed by atezolizumab and bevacizumab (TARZAN) not-yet-due
Ongoing 2018-002885-38 Trastuzumab-emtansine and osimertinib combination treatment to target HER2 bypass track resistance in EGFR mutation positive NSCLC not-yet-due
Ongoing 2018-003346-17 Phase III Randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy: OVHIPEC-2 not-yet-due
Ongoing 2018-004032-29 Effect of the moderate CYP3A4-inhibitor erythromycin on the pharmacokinetics of palbociclib not-yet-due
Exempt 2018-004148-53 ICRA (Improve Checkpoint-blockade Response in Advanced urothelial cancer), an adaptive clinical study to determine efficacy of combining weekly paclitaxel with tremelimumab +/- durvalumab (MEDI4736) not-yet-due
Ongoing 2018-004188-30 Pre-operative phase II trial for breast cancer with nivolumab in combination with novel IO not-yet-due
Ongoing 2018-004798-29 Track and treat in NSCLC (TATIN) – ctDNA guided treatment of early resistance to targeted treatment in patients with EGFR positive NSCLC not-yet-due
Ongoing 2018-004854-12 An Open-label Single-arm Pharmacokinetic Trial, Investigating the Effect of CYP3A4 inhibitor Ritonavir on the Pharmacokinetics of Erlotinib not-yet-due
Ongoing 2019-000851-15 Treatment of metastatic vulvar carcinoma in a neoadjuvant setting with Carboplatin and Paclitaxel chemotherapy not-yet-due
Ongoing 2019-003022-24 INFLUENCE (INtra-operative evaluation of a novel FLUorescENt C-mEt tracer in penile and tongue cancer) not-yet-due
Ongoing 2019-003104-12 Treatment of locally advanced VULvar CArcinoma in a Neoadjuvant setting with Carboplatin and Paclitaxel chemotherapy not-yet-due
Ongoing 2020-000849-14 Monalizumab and trastuzumab In Metastatic HER2-pOStive breAst cancer: MIMOSA-trial not-yet-due